Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
Cipla
Mallinckrodt
QuintilesIMS
UBS
Fish and Richardson
Deloitte
Harvard Business School

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NETUPITANT; PALONOSETRON HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Netupitant; Palonosetron Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT01339260 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Parexel Phase 3 NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
NCT01339260 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Helsinn Healthcare SA Phase 3 NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
NCT01376297 A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Parexel Phase 3 NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT01376297 A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Helsinn Healthcare SA Phase 3 NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT02517021 A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting Completed PSI CRO AG Phase 3 NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT02517021 A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting Completed Helsinn Healthcare SA Phase 3 NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Netupitant; Palonosetron Hydrochloride

Condition Name

Condition Name for Netupitant; Palonosetron Hydrochloride
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 6
Nausea and Vomiting, Chronic 1
Cervical Cancer 1
Malignant Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Netupitant; Palonosetron Hydrochloride
Intervention Trials
Vomiting 9
Nausea 7
Neoplasms 2
Uterine Cervical Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Netupitant; Palonosetron Hydrochloride

Trials by Country

Trials by Country for Netupitant; Palonosetron Hydrochloride
Location Trials
United States 55
Ukraine 4
Poland 3
Serbia 3
Russian Federation 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Netupitant; Palonosetron Hydrochloride
Location Trials
Florida 4
Ohio 4
California 4
Indiana 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Netupitant; Palonosetron Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Netupitant; Palonosetron Hydrochloride
Clinical Trial Phase Trials
Phase 3 4
Phase 2/Phase 3 2
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Netupitant; Palonosetron Hydrochloride
Clinical Trial Phase Trials
Recruiting 4
Completed 3
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Netupitant; Palonosetron Hydrochloride

Sponsor Name

Sponsor Name for Netupitant; Palonosetron Hydrochloride
Sponsor Trials
Helsinn Healthcare SA 7
Parexel 2
PSI CRO AG 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Netupitant; Palonosetron Hydrochloride
Sponsor Trials
Industry 10
Other 7
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fuji
Accenture
Express Scripts
Julphar
McKinsey
Chubb
Citi
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.